EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cefiderocol Treatment for Patients with Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa Infections in the Compassionate Use Program

Michael J Satlin iD, Patricia J Simner iD, Christine M Slover, Yoshinori Yamano, Tsutae D Nagata, Simon Portsmouth iD

Antimicrobial Agents and Chemotherapy · 18.07.2023 · 67 (7)

DOI: 10.1128/aac.00194-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 18.07.2023. Verfasst von Michael J Satlin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Transplant-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, New York,…. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Pseudomonas Infections. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cefiderocol is an option for infections caused by multidrug-resistant Pseudomonas aeruginosa , but its in vitro activity against these isolates and its clinical effectiveness for isolates with MICs of >1 μg/mL is unclear. We investigated the in vitro activity of cefiderocol against P. aeruginosa isolates collected from patients treated with cefiderocol through the compassionate use program and assessed physician-reported clinical response and 28-day all-cause mortality by cefiderocol MIC values. P. aeruginosa isolates underwent susceptibility testing to cefiderocol and comparator agents by using reference broth microdilution.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsPseudomonas InfectionsHumansPseudomonas aeruginosaCompassionate Use TrialsCephalosporinsCeftazidimeCarbapenemsMicrobial Sensitivity TestsDrug Resistance, Multiple, BacterialCefiderocol

Stichwörter der Autor:innen

carbapenem-resistant Pseudomonas aeruginosacefiderocolclinical responsecompassionate usesusceptibility breakpoint

Substanzen

Anti-Bacterial AgentsCephalosporinsCeftazidimeCarbapenemsCefiderocol

Autor:innen und Institutionen

  • Transplant-Oncology Infectious Diseases Program, Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, New York, USA.
  • Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Shionogi Inc., Florham Park, New Jersey, USA.
  • Shionogi & Co., Ltd., Osaka, Japan.

ORCID-Profile: Michael J Satlin, Patricia J Simner, Simon Portsmouth

Zitieren

APA

Satlin, M. J., Simner, P. J., Slover, C. M., Yamano, Y., Nagata, T. D., & Portsmouth, S. (2023). Cefiderocol Treatment for Patients with Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa Infections in the Compassionate Use Program. Antimicrobial Agents and Chemotherapy, 67(7). https://doi.org/10.1128/aac.00194-23

Vancouver

Satlin MJ, Simner PJ, Slover CM, Yamano Y, Nagata TD, Portsmouth S. Cefiderocol Treatment for Patients with Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa Infections in the Compassionate Use Program. Antimicrobial Agents and Chemotherapy. 2023;67(7). doi:10.1128/aac.00194-23

BibTeX
@article{Satlin2023,
  author = {Satlin, Michael J and Simner, Patricia J and Slover, Christine M and Yamano, Yoshinori and Nagata, Tsutae D and Portsmouth, Simon},
  title = {Cefiderocol Treatment for Patients with Multidrug- and Carbapenem-Resistant Pseudomonas aeruginosa Infections in the Compassionate Use Program},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2023},
  volume = {67},
  number = {7},
  doi = {10.1128/aac.00194-23}
}
Kostenlos starten →